{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T06:55:13Z","timestamp":1758264913482,"version":"3.33.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.msard.2024.105543","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:40:45Z","timestamp":1710607245000},"page":"105543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in Argentina: Data from the Argentinean registry"],"prefix":"10.1016","volume":"85","author":[{"given":"Juan I.","family":"Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2024.105543_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014433","article-title":"Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study","volume":"7","author":"Arroyo","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.msard.2024.105543_bib0002","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.msard.2024.105543_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1352458519898590","article-title":"Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients","volume":"27","author":"Carnero Contentti","year":"2021","journal-title":"Mult. Scler."},{"issue":"10076","key":"10.1016\/j.msard.2024.105543_bib0004","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.105543_bib0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1471-2377-11-127","article-title":"Validation of the Spanish version of the multiple sclerosis international quality of life (Musiqol) questionnaire","volume":"11","author":"Fernandez","year":"2011","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105543_bib0006","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105543_bib0007","article-title":"Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results from MS PATHS","volume":"7","author":"Hersh","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2024.105543_bib0008","series-title":"Designing Clinical Research: An Epidemiologic Approach","first-page":"80","author":"Hulley","year":"2013"},{"issue":"7","key":"10.1016\/j.msard.2024.105543_bib0009","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40263-017-0444-x","article-title":"Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs","volume":"31","author":"Jongen","year":"2017","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.msard.2024.105543_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2024.105543_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185931","article-title":"A systematic review of the effectiveness of self-management interventions in people with multiple sclerosis at improving depression, anxiety and quality of life","volume":"12","author":"Kidd","year":"2017","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.msard.2024.105543_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7224\/1537-2073.2016-039","article-title":"Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of US patients","volume":"19","author":"Mansfield","year":"2017","journal-title":"Int. J. MS Care"},{"issue":"10","key":"10.1016\/j.msard.2024.105543_bib0013","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105543_bib0014","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bmjspcare-2020-002604","article-title":"Global, regional and national quality of life in patients with multiple sclerosis: a global systematic review and meta-analysis","volume":"12","author":"Pashazadeh Kan","year":"2022","journal-title":"BMJ Support. Palliat. Care"},{"issue":"1","key":"10.1016\/j.msard.2024.105543_bib0015","article-title":"Access and barriers to MS care in Latin America","volume":"3","author":"Rivera","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2024.105543_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103038","article-title":"Research priorities in multiple sclerosis in Latin America: a multi-stakeholder call to action to improve patients care: research priorities in MS in LATAM","volume":"53","author":"Rojas","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105543_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.msard.2019.05.004","article-title":"The Argentinean multiple sclerosis registry (RelevarEM): methodological aspects and directions","volume":"32","author":"Rojas","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2024.105543_bib0018","first-page":"45","article-title":"Effectiveness and safety of early high-efficacy versus escalation therapy in relapsing-remitting multiple sclerosis in Argentina","volume":"45","author":"Rojas","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2024.105543_bib0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vhri.2022.04.001","article-title":"Preferences for disease-modifying therapies in argentina: cross-sectional conjoint analysis of patients and neurologists","volume":"31","author":"Rojas","year":"2022","journal-title":"Value Health Reg. Issues"},{"issue":"10","key":"10.1016\/j.msard.2024.105543_bib0020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/00023210-200822100-00004","article-title":"Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment","volume":"22","author":"Rudick","year":"2008","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.msard.2024.105543_bib0021","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458518807082","article-title":"The multiple sclerosis care unit","volume":"25","author":"Soelberg Sorensen","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2024.105543_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105543_bib0023","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7224\/1537-2073.2013-053","article-title":"Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis","volume":"17","author":"Wilson","year":"2015","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2024.105543_bib0024","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3389\/fneur.2017.00729","article-title":"Quality of life assessment in multiple sclerosis: different perception between patients and neurologists","volume":"8","author":"Ysrraelit","year":"2017","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105543_bib0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12883-019-1441-0","article-title":"Adaptation and validation of a Spanish version of the treatment burden questionnaire in patients with multiple sclerosis","volume":"19","author":"Ysrraelit","year":"2019","journal-title":"BMC Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824001226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:40:52Z","timestamp":1738064452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824001226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":25,"alternative-id":["S2211034824001226"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105543","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in Argentina: Data from the Argentinean registry","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105543"}}